BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36192661)

  • 1. Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.
    Masamoto Y; Taoka K; Maki H; Kurokawa M
    Ann Hematol; 2022 Dec; 101(12):2795-2797. PubMed ID: 36192661
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
    Le Gouill S; Beldi-Ferchiou A; Alcantara M; Cacheux V; Safar V; Burroni B; Guidez S; Gastinne T; Canioni D; Thieblemont C; Maisonneuve H; Bodet-Milin C; Houot R; Oberic L; Bouabdallah K; Bescond C; Damaj G; Jaccard A; Daguindau N; Moreau A; Tilly H; Ribrag V; Delfau-Larue MH; Hermine O; Macintyre E
    Lancet Haematol; 2020 Nov; 7(11):e798-e807. PubMed ID: 32971036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction.
    Hara T; Suzuki R; Ohno A; Yamakawa K; Yamagishi Y; Sugiyama Y; Sobajima T; Yamada R; Matsumoto R; Ikeda Y; Murayama M; Tsurumi H
    Int J Hematol; 2020 Apr; 111(4):585-590. PubMed ID: 31848991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
    Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
    Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.
    Topp MS; Duell J; Guijarro AMA; Odin M; Nielsen T; Rajeswaran A; Wenger M; Zundel C; Bogucka-Fedorczuk A; Wrobel T
    Haematologica; 2020 May; 105(5):e256-e260. PubMed ID: 32029506
    [No Abstract]   [Full Text] [Related]  

  • 9. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
    Radford J; Davies A; Cartron G; Morschhauser F; Salles G; Marcus R; Wenger M; Lei G; Wassner-Fritsch E; Vitolo U
    Blood; 2013 Aug; 122(7):1137-43. PubMed ID: 23843495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature.
    Lupia T; Corcione S; Staffilano E; Bosio R; Curtoni A; Busca A; De Rosa FG
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541221
    [No Abstract]   [Full Text] [Related]  

  • 11. The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany.
    Hofmann S; Himmler S; Ostwald D; Dünzinger U; Launonen A; Thuresson PO
    J Comp Eff Res; 2020 Oct; 9(14):1017-1026. PubMed ID: 33016109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of obinutuzumab in the management of follicular lymphoma.
    O'Nions J; Townsend W
    Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
    Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of Infusion-Related Reactions due to Obinutuzumab Therapy for Follicular Lymphoma.
    Azuma K; Matsuo K; Nemoto M; Uekusa S; Yokoyama M; Terui Y; Hama T; Yoshio T
    Gan To Kagaku Ryoho; 2021 Nov; 48(11):1369-1373. PubMed ID: 34795129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
    Bachy E; Houot R; Feugier P; Bouabdallah K; Bouabdallah R; Virelizier EN; Maerevoet M; Fruchart C; Snauwaert S; Le Gouill S; Marolleau JP; Molina L; Moluçon-Chabrot C; Thieblemont C; Tilly H; Bijou F; Haioun C; Van den Neste E; Fabiani B; Meignan M; Cartron G; Salles G; Casasnovas O; Morschhauser F
    Blood; 2022 Apr; 139(15):2338-2346. PubMed ID: 34936697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.
    Ueda Y; Asakura S; Wada S; Saito T; Yano T
    Intern Med; 2022 Aug; 61(16):2523-2526. PubMed ID: 35650124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
    Fujiwara Y; Urata T; Niiya D; Yano T; Nawa Y; Yoshida I; Imai T; Sunami K; Fujii S; Ennishi D; Maeda Y; Hiramatsu Y
    Int J Hematol; 2022 Jun; 115(6):811-815. PubMed ID: 35583725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.